The NLA is currently providing funding for world leading research into the molecular mechanisms that cause acute myeloid leukaemia (AML).
Dr Martin Grundy is a Postdoctoral research fellow within the department of Blood Cancer and Stem Cells at the University of Nottingham.
Martin previously worked for the NHS where he was involved in several AML clinical trials and research projects. Martin then completed his PhD at the University of Nottingham, investigating the therapeutic benefit of a novel aurora kinase targeting drug in AML. In 2019, Martin joined the University of Nottingham at the brand new Biodiscovery Institute, a state-of-the-art laboratories and research space that houses ~350, academics, clinicians, researchers and PhD students. Martin has expertise in numerous laboratory techniques, but his current focus is high resolution confocal microscopy and live imaging. The aim of his research is using these advanced imaging techniques to investigate the molecular mechanisms underpinning a commonly occurring sub-type of AML that have mutations in the (Nucleophosmin) NPM1 gene. Martins research has identified a yet undiscovered molecular mechanism underlying NPM1 mutated AML, providing new treatment potential in this hard-to-treat disease.
This research aims to identify novel therapeutic vulnerabilities that will improve treatment options for patients with AML.
Comments